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ABSTRACT
The latent HIV reservoir is a major impediment to curing HIV infection. The contribution of CD4 T cell activation status to the
establishment andmaintenance of the latent reservoir was investigated by enumerating viral DNA components in a cohort of 12
individuals commencing antiretroviral therapy (ART) containing raltegravir, an integrase inhibitor. Prior to ART, the levels of
total HIV DNAwere similar across HLA-DR and HLA-DR (HLA-DR) CD38memory CD4 T cell phenotypes; episomal
two-long terminal repeat (2-LTR) HIV DNA levels were higher in resting (HLA-DR CD38) cells, and this phenotype exhibited
a significantly higher ratio of 2-LTR to integrated HIVDNA (P 0.002). After 1 year of ART, there were no significant differ-
ences across each of the memory phenotypes of any HIVDNA component. The decay dynamics of integrated HIVDNAwere
slow within each subset, and integrated HIVDNA in the resting HLA-DR CD38 subset per mm3 of peripheral blood exhibited
no significant decay (half-life of 25 years). Episomal 2-LTRHIVDNA decayed relative to integrated HIVDNA in resting cells
with a half-life of 134 days. Surprisingly, fromweek 12 on, the decay rates of both total and episomal HIV DNAwere lower in
activated CD38 cells. By weeks 24 and 52, HIV RNA levels in plasma were most significantly correlated with the numbers of
resting cells containing integrated HIVDNA. On the other hand, total HIV DNA levels in all subsets were significantly correlated
with the numbers of HLA-DR CD38 cells containing integrated HIVDNA. These results provide insights into the interrelat-
edness of cell activation and reservoir maintenance, with implications for the design of therapeutic strategies targeting HIV per-
sistence.
IMPORTANCE
It is generally believed that HIV is not cleared by extensive antiretroviral therapy (ART) due to the difficulty in eradicating the
latent reservoir in resting CD4 T cells. New therapies that attempt to activate this reservoir so that immune or viral cytopathic
mechanisms can remove those infected cells are currently being investigated. However, results obtained in this research indicate
that activation, at least on some level, already occurs within this reservoir. Furthermore, we are the first to describe the dynamics
of different HIV DNA species in resting and activated memory CD4 T cell subsets that point to the role different levels of acti-
vation play in maintaining the HIV reservoir.
HIV antiretroviral therapy (ART) quickly reduces the pool ofinfected, activated CD4 T cells responsible for the vast ma-
jority of virions observed in peripheral blood, reduces inflamma-
tion, and increases CD4 T cell counts to levels closer to nor-
malcy, but there the progress toward elimination of this chronic
infection generally ends. This lack of progress is reflected in vivo by
rapid recrudescence if ART is interrupted and also recorded by
two ex vivomeasures of infection: (i) plasma viral levels (pVL) that
are continually present at low levels and observable with ultrasen-
sitive assays in many patients and (ii) measures of HIV DNA
within CD4 T cells. Although current therapies result in the lat-
ter measures decreasing in size and form, the latent reservoir of
replication-competent integrated HIV DNA in long-lived resting
CD4 T cells decays at rates that make it virtually refractory to
treatment (1). It is this hurdle that is engendering other therapeu-
tic approaches that hope to sufficiently activate latently infected
cells, allowing accelerated depletion and removal of the reservoir
well within an infected person’s lifetime.
However, the process by which the latent reservoir is estab-
lished and maintained is not clearly understood. Although quies-
cent cells can be infected with HIV, in vitro experiments have
established that complete reverse transcription to HIV DNA is
more likely in proliferating cells (2, 3). Latent infection, where
replication-competent HIV DNA is integrated into the host cell
genome but is not transcribed, can occur directly in resting cells
(4), but it is believed that this mostly occurs when activated cells
with integrated HIV DNA convert to a resting state as part of the
process ofmemory cell generation (5). There is an ongoing debate
regarding the extent to which direct infection of resting cells plays
in sustaining this reservoir in vivo. The degree to which cellular
activation acts to decrease and/or regenerate this reservoir is also
unclear.
AlthoughHIVDNA components have been studied longitudi-
nally in peripheral blood mononuclear cells (PBMC) or CD4 T
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cells and by viral outgrowth studies in resting CD4 T cells (1,
6–8), a comparison of their dynamics between resting and acti-
vated phenotypes has not previously been performed. A better
characterization of the relative contributions of these linked com-
partments is critical to a complete understanding of the dynamics
of the reservoir and the rational design of therapeutic interven-
tions.
Here we analyze data from a well-defined cohort of therapy-
naive HIV-infected individuals who were treated with ART in-
cluding the integrase inhibitor raltegravir (RAL) during either pri-
mary HIV infection (PHI) or chronic HIV infection (CHI) (the
PINT Study [9, 10]). In order to establish amore complete picture
of the mechanisms contributing to the latent reservoir, we com-
pared the dynamics of three components of HIV DNA, total, ep-
isomal (two-long terminal repeat [2-LTR]), and integrated HIV
DNA longitudinally over 1 year. Each of these HIV DNA compo-
nents was determined within stringently defined resting and acti-
vated memory CD4 T cell subsets, since the majority of HIV
DNA is contained within memory (CD45RO) CD4 T cells (11,
12). These resting and activated T cell subsets were defined by the
differential expression of the activation markers CD38 and HLA-
DR. We found persistence of all forms of HIV DNA in activated
memoryCD4T cells, long after the decrease in cellular activation
that accompanies suppression of viral replication with ART, sug-
gesting that there is continual de novo replenishment of this com-
ponent of the reservoir either by reactivation of infected resting
cells or by new infection.
MATERIALS AND METHODS
At weeks 0, 12, 24, and 52, 200 ml of whole blood was obtained by vene-
section from 6 PHI and 6 CHI patients enrolled in the PINT Study (9, 10),
where each of these antiretroviral-naive patients received ART commenc-
ing at week 0 consisting of RAL plus the reverse transcriptase inhibitors
tenofovir and emtricitabine. The study protocol was approved by the
Human Research Ethics Committee at St. Vincent’s Hospital (07/SVH/
89). Written informed consent was obtained from each participant. Sub-
sets of CD4 CD45RO T cells, based on coexpression of the CD38 and
HLA-DR activation markers, were purified from cryopreserved patient
PBMC by cell sorting using a FACSAria as previously described (13). At
baseline, cells were sorted into the HLA-DR CD38 (resting), HLA-
DRCD38, HLA-DRCD38 (activated), andHLA-DRCD38phe-
notypes. After week 12, due to the very low proportion of HLA-DR
CD38 activated CD4 CD45RO cells, the sorting strategy was modi-
fied to sort cells into the HLA-DR CD38 (resting), HLA-DR CD38,
and CD38 phenotypes (Fig. 1). Results of preliminary experiments
clearly demonstrated that the summing of the DNA levels in the two
sorted activated subsets gave equivalent results to the estimations of DNA
viral load in the sorted CD38 population (data not shown). To ensure
the estimations of DNA content of each subset were strictly restricted to
the individual subsets, we included in the analysis only the cells that sat-
isfied stringent flow cytometry gating for HLA-DR and CD38 expression
(Fig. 1A). Hence, we excluded a proportion of memory cells that had
intermediate expression levels of these molecules from the sorting gates,
resulting in purity of sorted populations exceeding 95% in every case. This
meant that summing HIV DNA levels over these memory subsets will
differ from estimates over the total CD4 T cell population (10). The
definition of HLA-DRCD38memory CD4 T cells as resting cells was
supported by the lowbackground levels of Ki-67 expression (1%) in this
subset compared to much higher levels in the 3 other memory subsets
(ranging from 6% to 29% Ki-67 at week 0).
Total, integrated, and episomalHIVDNA (2-LTR) copies per 106 cells
within each subset were determined as previously described (9), with lim-
its of quantification (LOQ) of 125 copies per 106 cells. HIV RNA cop-
ies/ml of plasmawere determined by an assaywith a LOQof 0.3 copies per
ml (14). Total cellular DNA was extracted from the purified memory
CD4 T cell subsets, and total HIV DNA was quantified by a real-time
PCR assay specific for each HIV DNA subspecies. Primers and probes
were selected based on sequencing data for individual patients. All assay
outputs providing results below the assay LOQ were set at the LOQ.
Copies of each HIV DNA component per 106 cells of a CD4 T cell
subset xwere converted to a value for copies per mm3 of peripheral blood
y within that subset, through the formula y (x/106)(q/100)(a), where q
is the percentage of the subset per memory CD4 T cells, and a is the
number of memory (CD45RO) CD4 T cells/mm3. Correlations be-
tween plasma viral levels (pVL) and HIV DNA components in different
subsets were determined as Spearman rank correlations. Comparisons
between groups were performed with a Wilcoxon rank sum test, and a
significance value of P 0.05 was chosen. Comparison across more than
2 groups was performed by the Kruskal-Wallis test. Single-phase and bi-
phasic decay curves for the HIV DNA species in each subset were deter-
mined with mixed-effects models.
Some of the correlations betweenHIVDNA components/mm3 in dif-
ferent cell subsets will be significant, say between a component i and a
component j, because each is correlated with another component, k. We
eliminated these inherited correlations by determining the shortest paths be-
tweeneachof theHIVDNAcomponents thatwere linked through significant
correlations, with weights on each connection given bylog(1 pij) where
pij is the significance of the correlation joining i and j. Shortest paths (that
extracted these reduced significant correlations) between all nodes (total,
2-LTR, episomalHIVDNA/mm3permemoryCD4Tcell subset)were then
determined usingDijkstra’smethod (graphshortestpath,Matlab 2012a). The
reduced significant correlations consisted of all correlations contained in at
least one of the shortest paths.
RESULTS
HIV DNA prior to ART. Although resting CD4 T cells can be
infectedwithHIV, in vitro experiments have established that com-
plete reverse transcription of HIV DNA is much more efficient in
proliferating cells (2, 3). However, this restriction prior to com-
pletion of reverse transcription in resting cells was not evident in
our ex vivo analysis, since total HIV DNA was equally likely to be
found in each of the subsets of memory CD4T cells regardless of
activation status prior to the commencement of ART at week 0
(P  0.43 for difference between subsets) (Fig. 2). Between 5%
and 11% (these and subsequent percentages are upper bounds
assuming a single HIV DNA copy per infected cell [15]) of these
memory CD4T cells contained total HIVDNA. It was less likely,
though it did not reach statistical significance (P 0.09), that this
total, and mostly linear, HIV DNA, successfully proceeded to in-
tegration in resting (HLA-DR CD38) cells. Only 0.08% of
HLA-DR CD38 cells contained integrated HIV DNA com-
pared to the other phenotypes (0.25% of HLA-DR CD38,
0.29% of HLA-DR CD38, 0.38% of HLA-DR CD38). This
poorer completion rate from linear to integrated HIV DNA in
resting cells was also reflected in these cells containing signifi-
cantly higher levels of abrogated infection represented by the pres-
ence of episomal (2-LTR) HIV DNA compared to activated cells
(HLA-DRCD38, P 0.02). The lower success rate of incorpo-
ration of HIV DNA within the genome of resting memory cells
was further supported by higher ratios of total to integrated HIV
DNA copies (median value of 62 for HLA-DR CD38 cells ver-
sus 15 for HLA-DR CD38 cells; P 0.047; Table 1) and higher
ratios of 2-LTR to integrated HIV DNA copies (P 0.002). Acti-
vated memory cells were also less likely to contain 2-LTR in PHI
than in CHI (0.01% versus 0.39%; P 0.03; Fig. 2).
A much lower proportion of resting cells carried the cellular
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FIG 1 Sorting strategy for resting and activated memory CD4 T cells for a typical PHI patient at two different times. (A) Sorting strategy for resting and activated
memory CD4 T cells for a typical PHI patient at week 0 into the 4 memory CD4 T cell subsets, HLA-DR CD38, HLA-DR CD38, HLA-DR CD38, and
HLA-DRCD38 cells. (B) Sorting strategy for resting and activatedmemory CD4T cells for a typical PHI patient at week 52 into the 3memory subsets, HLA-DR
CD38, HLA-DR CD38, and CD38 cells. Abbreviations: 50K, 50,000; FSC, forward scatter; SSC, side scatter; PerCP, peridinin chlorophyll protein; PE,
phycoerythrin.
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proliferation marker Ki-67 compared to activated cells (0.86% of
HLA-DR CD38 cells versus 28.69% of HLA-DR CD38 cells
at week 0; Fig. 3), with high but intermediate values found in the
other phenotypes (6.19% for HLA-DR CD38 cells and 11.29%
for HLA-DR CD38 cells). The only statistically significant dif-
ference of Ki-67 levels between PHI and CHI was higher prolifer-
ation for PHI within resting cells (1.1% versus 0.4%; P  0.03).
There was a 7-fold-higher proliferation rate in the HLA-DR
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FIG 2 Week 0 andweek 52 levels of total, 2-LTR, and integratedHIVDNAcopies per 106 cells for each cell subset, separated into PHI andCHI. Each symbol represents
the value for an individual. The short horizontal lines show themedian values for groups. The only statistically significant difference for all patients (combined PHI and
CHI) across all cell subsets and at either time pointwas for 2-LTRHIVDNAatweek 0 (P 0.02), where levels were higher in the restingHLA-DRCD38 subset than
in the activated HLA-DRCD38 subset (median value of 8,906 versus 1,963 copies per 106 cells).Within each subset, levels differed significantly for PHI versus CHI
only for 2-LTRHIVDNA levels in the activatedHLA-DRCD38 subset at week 0 (125 copies per 106 cells for PHI versus 3,875 copies per 106 cells for CHI;P 0.03)
and for integrated HIVDNA levels in the CD38 subset at week 52 (263 copies per 106 cells for PHI versus 700 copies per 106 cells for CHI; P 0.048).
TABLE 1 Median ratios of HIV DNA subspecies in resting/activated memory CD4 T cells prior to ART
Ratio of HIV DNA
subspeciesa
Group or
parameterb
Median HIV DNA ratioc in the following cells:
P value (across
subsets)d
HLA-DR
CD38
HLA-DR
CD38
HLA-DR
CD38
HLA-DR
CD38
Total/2-LTR All 12 18 64 23 0.1
PHI 10 18 90 20
CHI 17 17 18 26
P value 0.3 1 0.1 1
Total/INT All 62 57 15 46 0.047
PHI 103 40 12 33
CHI 55 57 15 53
P value 0.9 0.8 0.5 0.5
2-LTR/INT All 14 2.3 0.8 1.1 0.002
PHI 14 1.3 0.2 1.0
CHI 10 2.7 1.3 2.5
P value 0.6 0.4 0.3 0.3
a The ratios of total, 2-LTR, and integrated (INT) HIV DNA subspecies are shown.
b All individuals (All) and individuals with primary HIV infection (PHI) or chronic HIV infection (CHI) are shown. The significance of differences within each subset between PHI
and CHI is displayed in the P value row for each HIV DNA ratio.
c Subsets that are significantly different are shown in boldface type with or superscript for higher and lower, respectively.
d Significance of differences across the four subsets over all individuals.
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CD38 cells than in the HLA-DR CD38 cells, which should
lead to a continual dilution of episomal HIV DNA, but surpris-
ingly, the median 2-LTR levels were virtually the same.
Effect of ART including raltegravir on HIV DNA. Previous
investigations by our group and others have uncovered a generally
biphasic decay of HIV DNA and its subspecies with the com-
mencement of ART (6, 10, 16–18), including ART commenced
during PHI (19). The exception is an initial increase in 2-LTRHIV
DNA if an integrase inhibitor is part of the regimen (10). These
observations have been made in either bulk PBMC or in purified
bulk CD4 T cells which are heterogeneous in their makeup.
Studies of viral dynamics suggest that the initial decline in pVL
occurs in parallel with the decline in productively infected CD4
T cells (20, 21), while analyses over longer time scales have deter-
mined a slow decay of replication-competent latent infection in
resting CD4 T cells (1). Therefore, we expected total and inte-
grated HIV DNA levels to decay quickly with ART to minimal
levels in subsets of activated cells, with a smaller decline in HIV
DNA species in resting cells. Due to constraints in quantifying
HIV DNA within smaller subsets and the rapid decrease of num-
bers of activated cells following initiation of ART, from week 12
on, thememoryCD4T cells were sorted into a combinedCD38
(activated) phenotype and the two separate CD38 phenotypes
(HLA-DR CD38 and HLA-DR CD38). However, the ex-
pected differential decrease of HIV DNA between activated and
resting cells was not observed. After 1 year of ART, there were no
differences between CD38 and CD38memory CD4 T cells of
numbers of total, episomal, or integrated HIV DNA per 106 cells
(Fig. 2). This was despite a 21-fold-higher rate of proliferation, as
measured by Ki-67 expression, in the CD38 subset at week 52
(19.5% of CD38 memory CD4 T cells were Ki-67 compared
to only 0.8% of the CD38 subset; P 0.0002). As we had strin-
gently sorted each memory subset to 96% to 99% purity, this
result cannot be explained by contamination from the CD38
subset. However, the relative contribution of activated memory
CD4T cells to the cellular HIV reservoir is small, given themuch
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lower number of activated CD4T cells compared to their resting
counterparts, as we previously found in untreated chronically in-
fected subjects (13).
On the other hand, the dynamic changes over the course of the
year in these subsets were dependent on the activation status of the
cells and the particular HIV DNA component (Fig. 3). Total HIV
DNA copies/106 cells decayed in a biphasic manner within each
subset (P  106, likelihood ratio test comparison with single-
phase decay). The half-life of the slower second phase (week 12
onwards) was 178 days for the resting phenotype (HLA-DR
CD38), but surprisingly, it was even longer for the more acti-
vated subsets (Table 2), suggesting either ongoing infection or
cellular reactivation of resting cells containing HIV DNA. The
half-life calculations for each subset will be affected by degrada-
tion of unintegrated HIV DNA molecules within a cell, loss or
conversion to another phenotype, and conversion from another
phenotype. The half-lives calculated here are therefore summary
measures of all of these dynamic influences. A comparison of in-
dividual regression curves of log total HIV DNA from week 12
onwards confirmed the significantly faster second phase decay
within resting HLA-DR CD38 cells compared to HLA-DR
CD38 and CD38 cells (P 0.0004).
In this analysis, the decay of episomal HIV DNA was mostly
monophasic, although any peaks in this HIV DNA component
that were previously observed in bulk CD4 T cells at week 2 or 3
(10) would not have registered here, since collection of large vol-
umes of peripheral blood for cell sorting was necessarily limited.
Episomal HIV DNA decay in the HLA-DR CD38 subset was
markedly different from the dynamics in the other subsets, exhib-
iting rapid decay to below the assay LOQ. Decay rates of 2-LTR
from week 12 onwards were significantly lower in the activated
CD38 subset versus the restingCD38 subset (P 0.04), reflect-
ing the situation for total HIV DNA (Fig. 3).
The early decay of total HIV DNA/106 cells (measured by
change fromweek 0 to week 12) differed across phenotypes with a
faster loss within CD38 cells (27-day half-life; Table 2) than for
resting HLA-DR CD38 cells (47-day half-life, P  0.01). As
would be expectedwith the loss of the productively infected subset
at the start of ART, integrated HIV DNA also decayed faster over
the first 12weeks inCD38 cells than in restingHLA-DRCD38
memory CD4 T cells. In the latter subset, the decay of integrated
HIV DNA was essentially monophasic over the entire year (433-
day half-life; P 0.01). However, decay rates for integrated HIV
DNA fromweek 12 onwards did not differ across the subsets (P
0.6), which again was surprising given the very different Ki-67
profiles for each of these subsets (Fig. 3).
Half-lives of unintegrated HIV DNA molecules. Given the
relatively stable levels of integrated HIV DNA within the resting
memory phenotype and that these cells are likely long-lived (as
reflected by their lowproliferation rates), any loss of the otherHIV
DNA components in comparison to the integrated form should
represent decay of the HIV DNA species rather than the cell itself.
Hence, we estimated the decay rates of 2-LTR and total HIVDNA
relative to integrated HIV DNA/106 HLA-DR CD38 cells from
week 12 on (Fig. 4). Linear regression performed on each patient
for these ratios determined decay rates that were significantly dif-
ferent fromzerowithmedian half-lives of 134 days for 2-LTR (P
0.006) and 181 days for total HIV DNA (P 0.01).
Restingcellswith integratedHIVDNAare refractory toART.
Although the number of HIVDNA copies per 106 CD4 T cells of
any subset will change according to loss or expansion of the DNA
species and/or the cells containing them, their absolute numbers
in peripheral blood will also change with any expansion or con-
traction of cell numbers due to immune reconstitution with ART.
The absolute numbers of cells within each of the CD38 subsets
increased over timewhen calculated permm3 of peripheral blood.
To compensate for this effect, we converted HIV DNA copies per
106 cells toHIVDNA copies permm3 of peripheral blood for each
subset by taking into account the percentage of total CD4 T cells
per mm3 represented by each subset (Materials and Methods).
IntegratedHIVDNAwithin each of theCD38 cell subsets (num-
ber of copies of HIV DNA per mm3) exhibited decay rates from
week 12 on that did not differ statistically from zero (Fig. 5 and
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FIG 4 Decay of 2-LTR and total HIV DNA relative to integrated HIV DNA in
resting memory CD4 T cells. Decay of log10 of ratios of 2-LTR to integrated
HIV DNA copies (solid lines and symbols), and total to integrated HIV DNA
copies (dashed lines and open symbols) in the resting HLA-DR CD38
memory CD4 T cell phenotype from week 12. Individuals with integrated
HIV DNA below the assay LOQ were omitted.
TABLE 2 Half-lives of the 3 HIV DNA components per 106 cells of the
T cell subsetsa
HIV DNA
Half-life (days) of the indicated HIV DNA component
in the following T cell subset:
HLA-DR
CD38
HLA-DR
CD38 CD38 CD38
Total DNA 47, 178 32, 6,932b 43, 198 27, 462
2-LTR DNA 98 24,630c 99 173
Integrated DNA 433 64, 3,466b 116, 533 41, 433
a The half-lives of the three HIV DNA components per 106 cells are shown. Both a
monophasic curve and a biphasic curve (first phase from week 0 to week 12, with the
second phase from week 12 to week 52) were fitted to each data set using a nonlinear
mixed-effects method, where the initial value of the fitted curve included a random
effect, but each slope parameter was treated as a fixed effect. The best fitted curve was
determined using the likelihood ratio test. Entries with two half-lives recorded had the
biphasic curve as the best fit (half-lives of first and second phase, respectively);
otherwise, the single curve was the best fit and that half-life (t1/2 ln 2/k, for the slope
parameter k) is recorded (a negative half-life denotes a doubling time). When the
biphasic model was the best fit, the initial decay was limited by having data only for
weeks 0 and 12, so that the half-life reported there provides an upper bound. The
second phase half-life estimate of 2-LTR HIV DNA in the HLA-DR CD38 subset was
affected by the majority of individuals having levels below detection after week 12 (and
that were recorded as equal to the LOQ).
b The final phase decay rate was not significantly different from zero.
c From week 12 on, most 2-LTR HIV DNA levels per 106 HLA-DR CD38 were below
the assay LOQ.
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Table 3). The half-life of integrated HIV DNA within the resting
HLA-DR CD38 subset per mm3 was approximately 25 years.
Correlates of pVL and HIV DNA. We had previously deter-
mined that pVL in these patients declined quickly to a geometric
mean of 9 HIV RNA copies/ml by week 16, after which time pVL
was virtually constant (10). We assessed the connection between
viremia, which was above the limit of quantification of the single-
copy assay for all individuals at weeks 0 and 12 and for 10 of the 12
individuals at weeks 24 and 52, and each of the HIVDNA subspe-
cies and cell subsets through a correlation analysis at each of the
time points after first converting the data to comparable units
(copies of HIV RNA per ml and HIV DNA per mm3 of peripheral
blood). pVL at weeks 0, 12, and 52 were not correlated with any
HIV DNA component in any of the activated/resting memory
CD4 T cell subsets at their respective time points. At week 24 in
the constant third phase of decay (10), pVL was positively corre-
lated with levels of both integrated (P  0.003), and total (P 
0.01) HIV DNA in the resting HLA-DR CD38 cells/mm3 sub-
set.
Drivers of HIV replication within and between subsets. Fi-
nally, we investigated how the different HIV components in the
subsets were related. It is to be expected that some HIV DNA
copies observed within a phenotype may occur from infection
within that subset, while other copies will arise from infection in
another phenotype that subsequently changes phenotype or
changes from one HIV DNA subspecies (such as total) to another
(such as episomal or integrated).
Before the start of therapy at week 0, many of the HIV DNA
components in the different memory subsets were significantly
correlated (Fig. 6). In contrast, as viremia and cellular activation
decreased with ongoing treatment (Fig. 7), the number of these
correlations reduced as shown in the later time points of Fig. 6. At
week 0, total HIV DNA expressed as copies/mm3 in the activated
HLA-DR CD38 subset showed the most correlations, as de-
noted by the number of lines extending from that total HIV DNA
node to other nodes within the other subsets. Total HIV DNA in
this activated subset was significantly positively correlated with
integratedHIVDNAwithin the same subset, with total HIVDNA
in HLA-DR CD38 and HLA-DR CD38 cells, and addition-
ally with 2-LTR levels in resting HLA-DR CD38 cells. Further-
more, integrated HIV DNA numbers in the activated HLA-DR
CD38 subset correlated with integrated levels in both the HLA-
DR CD38 and HLA-DR CD38 subsets. This may be due to
cells containing integrated HIV DNA changing phenotype either
through reversion of activated cells to a resting phenotype or to
cellular activation of resting cells.
At week 12, a similar pattern was apparent. Total HIV DNA
levels in activated (CD38) cells continued to correlate with inte-
gratedHIVDNAwithin each of the other subsets (Fig. 6). By week
24, this pattern had changed. Activation had decreased as judged
by the reduction inHLA-DRCD38CD8T cells (Fig. 7) to the
point where the only correlations between HIV DNA subspecies
occurred within rather than between phenotypes (the lines repre-
senting significant correlations are contained wholly within each
sector of the week 24 graph). However, by week 52, when pVL had
been stable at low levels for some time, this situation altered so
that integrated HIV DNA in the HLA-DR CD38 subset was
correlated with total HIVDNA in all phenotypes. At this time, the
role of antigen-driven activation of CD4T cells has likely dimin-
ished, and homeostatic mechanisms may play a larger role in the
maintenance of infection.
DISCUSSION
Somewhat contrary to expectations, but consistent with previous
observations from our group and others (13, 22), we found total
HIV DNA to be present in equivalent proportions across all rest-
ing/activated subsets before the commencement of ART (Fig. 2).
These ex vivo results differ markedly from the results of in vitro
experiments that generally delineate the inability of HIV RNA to
complete reverse transcription in resting CD4 T cells (3, 23, 24),
although these studies did not differentiate memory from naive
cell populations but considered bulk resting CD4 T cell popula-
tions. On the other hand, downstream events such as the likeli-
hood of HIV DNA proceeding to integration rather than sponta-
neously circularizing to an episomal formwere certainly less likely
in resting cells (Table 1). This arrest in conversion of viral DNA to
integrated provirus may, for example, be related to a lack of host
proteins in restingmemory cells, such as BAF (barrier to autointe-
TABLE 3 Half-lives of the three HIV DNA components per mm3 of
whole blood for the T cell subsetsa
HIV DNA
Half-life (days) of the indicated HIV DNA component
in the following T cell subset:
HLA-DR
CD38
HLA-DR
CD38 CD38 CD38
Total DNA 75, 224 49, 689 68, 257 24, 365
2-LTR DNA 133 37c 142 139
Integrated DNA 8,978b 698c 1,442b 33, 385
a The half-lives of the three HIV DNA components per mm3 of blood are shown.
Model fitting was performed as described in Table 2, footnote a.
b The final phase decay rate was not significantly different from zero.
c From week 12 on, most 2-LTR HIV DNA levels per 106 HLA-DR CD38 cells were
below the assay LOQ. The conversion to a corresponding amount per mm3 was
therefore affected, and the second phase of this component per mm3 was omitted.
10−2
100
102
HLA−DR−CD38−
To
ta
l/m
m
3
HLA−DR+CD38− CD38− CD38+
10−2
100
102
2−
LT
R
/m
m
3
0 12 24 52
10−2
100
102
IN
T/
m
m
3
Weeks
0 12 24 52
Weeks
0 12 24 52
Weeks
0 12 24 52
Weeks
FIG 5 HIVDNApermm3 dynamics in resting/activatedmemory CD4T cell
subsets. HIVDNA components are shown as the number of copies permm3 of
memory CD4 T cell subsets in peripheral blood: HLA-DR CD38, HLA-
DR CD38, CD38, and CD38 (PHI shown in blue and CHI in red). The
median values are shown in green. The median values of the numbers of each
cell subset per mm3 are shown as black markers and lines.
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gration factor) that promote integration (25), or suboptimal levels
of cytokine signaling (26), but does not appear to be related to
differential expression of host enzymes that drive LTR formation
(unpublished observations). Despite this holdup, per cell levels of
integratedDNAdid not differ between the four subpopulations of
CD4 T cells prior to ART. Overall, this would suggest that for-
mation of the latent pool partially occurs through direct infection
of resting memory cells, as observed by others (27, 28), and does
not entirely arise when activated CD4 T cells at the point of
integrating HIV DNA into their genome revert to a resting mem-
ory state (5).
Furthermore, we found that HIV DNA did not reduce to min-
imal levels in activated CD38memory CD4 T cells after 1 year
of ART, despite approximately 20% of these cells undergoing pro-
liferation at this time. This is consistent with findings that despite
patients receiving ART for an average of 9.1 years, total HIVDNA
was still present in activated CD4 T cells (defined as CD25
CD69HLA-DR), and higher than levels in resting cells (CD25
CD69HLA-DR) (29). If the very high rate of turnover, as mea-
sured by expression of Ki-67, is homogeneous across the activated
CD38 CD45RO phenotype, then HIV DNA before ART or in
the early stages of ART could formonly a very small component of
levels in activated cells at 1 year. The vast majority will be from
new infection or activation of latently infected resting cells. Ho-
meostatic mechanisms which conceivably result in periodic acti-
vation followed by reversion to a resting state of memory CD4 T
cells could also contribute to the maintenance of the pool of acti-
vated cells containing HIV DNA, dependent on whether this
mechanism of cellular activation maintains latency. For example,
treatment with supraphysiological doses of interleukin 7 (IL-7)
appears to increase CD4 T cell counts effectively in patients on
stable ART, but the level of HIV DNA remains stable on a per
CD4 cell basis. As the total number of CD4 T cells increases,
this suggests that the total reservoir of HIV DNA increases with
this type of intervention (30).
Plasma viremia generally results from productive infection
within activated CD4 T cells prior to ART, whereas it has been
expected that the viral reservoir during ART is generally restricted
to resting latently infected cells (5). Our data demonstrating the
same proportion of integrated HIV DNA in each of the memory
CD4 T cell subsets regardless of CD38 expression is at odds with
the view that latent infection is maintained within an essentially
quiescent pool of resting cells. While ART reduces the proportion
of activated memory CD4 T cells from 11% to 2.9%, these acti-
vatedmemory cells still contain a high proportion of proliferating
cells after reductions in plasma viral load, and therefore likely
contribute to maintenance of the reservoir. Integrated viral DNA
Week 0
Week 12
Week 24 Week 52
CD38-HLA-DR-
CD38+HLA-DR- CD38+HLA-DR+
CD38-HLA-DR+
CD38+
2LTR
Total
Integrated
Productively infected
activated cells are
associated with infection
in all memory cells 
in the absence of ART
ART reduces infection 
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in activated cells.
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infection in all cells
possibly through
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FIG 6 Size of each HIV DNA component in resting and activated memory CD4 T cells during ART and significant correlations between them at each time
point. The size of each sector represents median values of total HIV DNA copies/mm3 in each of the CD38HLA-DR subsets. The median 2-LTR HIV DNA
copies/mm3 is represented by the area of the white circle within each sector. Themedian integratedHIVDNA copies/mm3 is represented by the area of the white
squarewithin each sector. Significant (reduced as described inMaterials andMethods) rank correlations betweenHIVDNAcomponents and subsets at each time
are shown as black lines, where a correlation with total HIVDNA is represented by a connection to that sector’s more centrally located yellow node. For example,
at week 0, the number of totalHIVDNAcopies/mm3 in the activatedCD38HLA-DR cells (represented by the green sectorwith correlations to totalHIVDNA
in this phenotype represented by lines connecting the inner node of this sector) shows the most correlations, significantly correlated with integrated HIV DNA
within the same subset but also with total HIVDNA in CD38HLA-DR and CD38HLA-DR cells, plus with 2-LTR levels in resting CD38HLA-DR cells.
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in this subset is unlikely to all be incompetent virus. Recent elegant
studies have demonstrated that although integrated HIV DNA
overestimates the replication-competent latent reservoir as mea-
sured by viral outgrowth assays from resting CD4 T cells (31),
these two measures are less distant than previously thought (32).
Therefore, even after sustained reductions in viral load, there are
as many integrated viral genomes in the activated memory cell
population as there are in resting memory cells on a per cell basis.
Our findings are not inconsistent with those of Chomont et al. (6).
Both data sets pose questions regarding the potential therapeutic
efficacy of exogenous T cell activation in reducing the reservoir, if
there is a similar process of cellular activation already proceeding
as part of the pathophysiology of treated HIV infection or if it is a
normal part of T cell homeostasis (6).
We observed some circumstantial evidence that cells contain-
ing HIV DNA can revert to a more resting status, a process that is
thought to generate latent infection. The 100-fold decrease in
2-LTRHIVDNA inHLA-DRCD38 cells over the first 12weeks
was not duplicated in the other subsets, and it possibly resulted
from these partially activated cells reverting to a HLA-DR
CD38 phenotype and carrying their episomal cargo with them
(Fig. 3). However, this same phenotypic conversion and transport
of HIV DNA were not observed for integrated HIV DNA. The
intermediate activated HLA-DR CD38 phenotype, in which
approximately 5% of cells consistently expressed Ki-67 (Fig. 3),
may increase their numbers through homeostatic proliferation,
thereby diluting episomal and other unintegratedHIVDNAwhile
doubling the integrated HIV DNA content. As these cells become
further activated, they can also reseed the CD38 compartment,
as we observed in the correlation of integrated HIVDNA inHLA-
DRCD38 cells/mm3 with integrated and total HIVDNA in the
CD38 subset at week 52 (Fig. 6).
The rate at which the latent reservoir decays under ART has
been determined by measuring HIV DNA copies in PBMC or
CD4 T cells and by examining viral outgrowth from resting
CD4 T cells (1, 7, 8, 17), with the subsequent analysis performed
on the change in these measures per fixed number of cells. The
decay of the percentage of resting cells containing latent infection
has been estimated to have a half-life of 44 months (1). However,
according to our estimates, this percentage of long-lived infected
cells changes not because the number of infected cells decreases
but because the number of uninfected resting cells increases with
immune reconstitution (Fig. 3). In this study, the absolute num-
ber, rather than the percentage, of resting memory cells contain-
ing integrated HIV DNA did not change with time (Table 3),
consistent with the results of Mexas et al. (33), suggesting that
even the long periods previously calculated for the eradication of
HIV infection on ARTmay underestimate its recalcitrance. How-
ever, our measurements were limited to a 1-year period, so they
may underestimate loss with additional treatment time. Other
investigators have observed pVL decline over a 3-year period after
the commencement of ART (34). On the other hand, the faster
dynamics of a raltegravir-containing regimen (35) feasibly results
in pVL reaching the latent third phase earlier, as observed in these
patients in a related study (10). The conversion from HIV DNA
copies per 106 cells to per mm3 also requires accurate estimates of
each cell subset per mm3, and although this is standard, it can
introduce additional error. This measure will also be affected by
perturbed trafficking, especially over the initial period of ART
when cellular activation remains elevated (Fig. 7), but less so over
the later period when our measure of latent decay was obtained.
Episomal HIVDNA numbers can decrease due to intracellular
degradation of 2-LTR circles but can also be lost through cell death
and diluted through cellular proliferation. To minimize the im-
pact of cell death and proliferation on delineating the dynamics of
this HIV DNA species, we compared changes in 2-LTR levels to
integrated HIV DNA in the resting HLA-DR CD38 subset.
Even in this minimally changing niche, 2-LTR HIV DNA de-
creasedwith a half-life of 134 days relative to integratedHIVDNA.
The loss of 2-LTR HIV DNA in CD4 T cells as a whole will be
affected by the underlying decay of this DNA species and the half-
lives of the cells being considered, and taking these differentmech-
anisms into considerationmay partly explain the controversy sur-
rounding in vitro and ex vivo 2-LTR decay estimates (18, 36–38).
Approximately 0.36% of these resting memory cells expressed the
proliferation marker Ki-67 after week 12. Since the percentage of
CD4T cells expressingKi-67 is approximately 5-fold higher than
the percentage of dividing cells (39), then approximately 0.07% of
these resting memory cells are dividing per day. Therefore, 2-LTR
HIVDNAwill decrease at this rate if episomal HIV DNA is lost to
the cytoplasm of dividing cells and is degraded, but cells contain-
ing integrated HIV DNA will increase at this same rate as these
cells divide. Hence, the ratio of 2-LTR to integrated HIV DNA
copies will decrease at 0.14% per day, giving a half-life of 495 days
for this ratio under cell division alone, much longer than the half-
life of 134 days observed here. This implies either a faster 2-LTR
decrease than due solely to cellular proliferation and/or additional
integratedHIVDNAarising in these resting cells through ongoing
infection. From week 12 on, 2-LTR HIV DNA decreased with
equivalent half-lives in each CD4 T memory cell subset regard-
less of their activation status and exhibited very different prolifer-
ation profiles. One explanation of this is that it reflects ongoing
infection that evades the block provided by the two reverse trans-
criptase inhibitors in this antiretroviral regimen but that is subse-
quently inhibited by the integrase inhibitor generating new epi-
somal HIV DNA (40).
It should be noted that relative levels of total and integrated
HIV DNA differ from other studies where these ratios are usually
lower both before and during ART (16). It may be that the PCR
assays used here overestimate total levels and/or underestimate
integratedHIVDNA levels depending on the distance atwhich the
viral genome integrates relative to Alu repeat elements (27). Assay
variation can explain some of this discrepancy; however, the anti-
retroviral regimenwill also contribute to themuch higher levels of
total versus integrated HIV DNA observed after commencement
of ART in this study, especially at later time points. Antiretroviral
regimens that do not include an integrase inhibitor result in total
HIV DNA levels approaching integrated HIV DNA levels, with
much lower 2-LTR levels (6, 16, 33). On the other hand, raltegra-
vir increases episomal HIV DNA both in vitro and in vivo while it
inhibits further integration events (10, 40, 41). Hence, it is to be
expected that 2-LTR levels will be elevated in our study and that
1-LTR levels that cannot be directly quantitatedmay also contrib-
ute to the total HIV DNA complement (40, 42), so that total HIV
DNA stays in excess of integrated HIV DNA (Fig. 2).
Furthermore, the conservative gates used for sorting memory
CD4 T cells into purified subsets omitted those cells with inter-
mediate values of CD38 and/or HLA-DR and their HIV DNA
cargo (or lack of it). Thismay have altered the amount of eachHIV
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DNA attributed to each subset of the memory CD4 T cell popu-
lation.Nevertheless, this is unlikely to affect comparisons between
subsets of the sameHIVDNA species or the estimates of the decay
rate that only take into account changes between successive time
points.
In the PINT Study, we found that 2-LTR HIV DNA per 106
CD4 T cells peaked approximately 3 weeks after the commence-
ment of this integrase inhibitor-containing ART regimen (9, 10).
The larger blood volumes required for the current investigation
precluded investigation of which resting/activatedmemory CD4
T cell subset was responsible for the peak observed in bulk CD4
T cells, but prior to commencement of ART, a mean of 0.6 HLA-
DR CD38memory cells per mm3 contained 2-LTR HIV DNA
compared to 0.02 HLA-DR CD38 cells and 0.12 CD38 cells.
At week 0, approximately half of the CD38 cells have a HLA-
DR phenotype. Given the fold differences in 2-LTR levels be-
tween all subsets, it seems likely that the peak in 2-LTRHIV DNA
originated in the HLA-DR CD38 subset, with possibly some
reversion from the more activated CD38 subsets where the as-
sembly line of linear unintegrated HIV DNA within these cells is
diverted to the 2-LTR track due to the effect of the integrase in-
hibitor. Reversion of activated cells to a more resting state would
be assisted by the decrease in activation induced by the effects of
ART. However, at the commencement of an antiretroviral regi-
men that does not contain an integrase inhibitor, instead of in-
creasing 2-LTR content within resting cells, many of these unin-
tegrated HIV DNA would proceed to integration, resulting in a
potential boost to the latent reservoir. For this reason, incorpora-
tion of an integrase inhibitor at least for the start of any antiretro-
viral regimen may be advantageous.
New therapies that attempt to flush out latent infection with
agents such as histone deacetylase (HDAC) inhibitors and others
such as disulfiram are under investigation (43, 44). Our results
suggest eradication strategies such as these aimed mainly at the
reactivation of latently infected resting CD4Tmemory cells may
face a difficult task, since we observed high levels of proliferation
in the more activated CD38 and HLA-DR CD38 memory
cells, and yet we saw no substantial decay in integrated HIV DNA
in these subsets.
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